M&A Advisory Saudi Arabia & GCC
Mergers and acquisitions in the Kingdom are accelerating, driven by Vision 2030 localization, privatization, sector consolidation, and rising international capital. For a buyer or a seller, the opportunity is real and so is the risk — most of which sits in the parts of a deal that do not appear in the headline price. A Saudi transaction runs through a regulatory frame that can reshape it, delay it, or stop it: the Capital Market Authority's rules where listed securities are involved, the General Authority for Competition's merger-control requirements, sector licensing, and foreign-ownership conditions. The CMA has also been building the architecture for more sophisticated deal-making, including a proposed framework for special-purpose acquisition companies and a squeeze-out/sell-out mechanism at the 90% ownership threshold. This hub collects Elevare Partners' analysis of M&A for Saudi acquirers, targets, and boards: defining the right target, testing the deal thesis through commercial diligence, mapping the approval path before committing, assessing synergies that survive contact with reality, and planning the integration where value is preserved or lost. Deals are won on preparation and discipline, not optimism. The number on the slide is rarely the number that matters.
Related insights
Frequently asked questions
Which regulators are involved in a Saudi M&A deal?
It depends on the structure. The General Authority for Competition handles merger control where thresholds are met. The CMA is involved when listed securities or public-company transactions are concerned, including takeover and disclosure rules. Sector regulators and the foreign-investment framework may also apply. Mapping the approval path early is essential, because conditions and timing can move the deal.
What is commercial due diligence, and why does it matter?
Commercial diligence tests whether a target's performance will continue and why — examining market position, the durability of revenue, competitive risks, and the assumptions behind the projections. Financial diligence shows what happened; commercial diligence asks whether it holds. It is an honest test of the deal thesis, not a confirmation of it.
How are synergies assessed credibly?
By distinguishing savings and growth that are practically achievable from those that are hypothetical, and by grounding the number in operational reality rather than presentation optimism. The synergy figure a board relies on should be one it can defend. Overstated synergies are the most common reason deals disappoint after closing.